Overview

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Examine the effects of deutetrabenazine on functional speech and gait impairment
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborator:
Teva Branded Pharmaceutical Products R&D, Inc.